Final answer:
NOACs and warfarin can both cause bleeding, but they work in different ways. Warfarin inhibits the production of vitamin K-dependent clotting factors, while NOACs directly target clotting factors. Risk of bleeding may vary depending on the patient, so consulting a healthcare professional is important.
Step-by-step explanation:
Both NOACs (Novel Oral Anticoagulants) such as rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis) and warfarin (Coumadin) can cause bleeding as a possible side effect, but they work in different ways.
Warfarin works by inhibiting the production of vitamin K-dependent clotting factors, while NOACs directly target specific clotting factors. Warfarin, being an older anticoagulant, has a longer half-life and more potential interactions with other medications or diet. NOACs generally have a shorter half-life and less interaction potential.
However, it's important to note that the risk of bleeding may vary depending on the individual patient, their medical history, and other factors, so it's crucial to consult with a healthcare professional for personalized advice.